{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:56:45Z","timestamp":1790816205466,"version":"4.1.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>The only therapy to ameliorate disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) is tolvaptan, a vasopressin V2 receptor antagonist. Real-life data on long-term tolvaptan treatment are sparse and limited by restricted follow-up, small patient groups or lack of a control group. We studied the long-term effect of tolvaptan on kidney function and kidney growth in real-life patients and controls. Moreover, we investigated determinants of long-term treatment efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the prospective DIPAK cohort and retrospective OBSERVA cohort were pooled. estimated glomerular filtration rate (eGFR) was measured at least yearly and total kidney volume (TKV) at least every 3\u00a0years. Treatment effects from the start to 6\u00a0weeks after initiation of tolvaptan were analyzed as \u201cacute slope.\u201d After this, endpoints were analyzed as \u201cchronic slope.\u201d As a control group, we included all patients who were not treated with tolvaptan, assessing change in endpoints before and during theoretical treatment (based on the average time of tolvaptan initiation in tolvaptan-treated patients).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 615 patients (48\u00a0\u00b1\u00a012\u00a0years, 58.2% female) were included in the full analysis, of which 105 (17.1%) were treated with tolvaptan. The average duration of treatment was 6.1\u00a0\u00b1\u00a04.7\u00a0years (range 0.8 to 15.9). After matching, two groups of 92 patients remained for matched analysis. In this analysis, tolvaptan reduced eGFR decline during chronic slope by 14.0% (\u20134.36 to \u20133.75\u00a0mL\/min\/1.73\u00a0m2\/year, P\u00a0=\u00a0.03), versus a decrease of 1.0% (\u20134.16 to \u20134.12\u00a0mL\/min\/1.73\u00a0m2\/year, P\u00a0=\u00a0.9) in the control group. Long-term TKV growth did not significantly change during tolvaptan treatment (5.05 to 5.59%\/year P\u00a0=\u00a0.6). In subgroup analyses, patients with a higher mean osmolar intake had a larger treatment effect of tolvaptan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this study, with real-life patient data, long-term follow-up and a well-matched control group, we found that tolvaptan attenuated long-term kidney function decline but seemed not to influence kidney growth.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf048","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:20:00Z","timestamp":1741159200000},"page":"1764-1774","source":"Crossref","is-referenced-by-count":8,"title":["The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-9727","authenticated-orcid":false,"given":"Paul","family":"Geertsema","sequence":"first","affiliation":[{"name":"University of Groningen Department of Nephrology, University Medical Center Groningen, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bais","sequence":"additional","affiliation":[{"name":"University of Groningen Department of Nephrology, University Medical Center Groningen, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Kuiken","sequence":"additional","affiliation":[{"name":"University of Groningen Department of Nephrology, University Medical Center Groningen, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1780-4899","authenticated-orcid":false,"given":"Martine G E","family":"Knol","sequence":"additional","affiliation":[{"name":"University of Groningen Department of Nephrology, University Medical Center Groningen, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek F","family":"Casteleijn","sequence":"additional","affiliation":[{"name":"University of Groningen Department of Urology, University Medical Center Groningen, , Groningen ,","place":["The Netherlands"]},{"name":"Ommelander Ziekenhuis Department of Urology, , Scheemda ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-820X","authenticated-orcid":false,"given":"Priya","family":"Vart","sequence":"additional","affiliation":[{"name":"University of Groningen Department of Nephrology, University Medical Center Groningen, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[{"name":"University of Groningen Department of Nephrology, University Medical Center Groningen, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"University of Groningen Department of Nephrology, University Medical Center Groningen, , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"2025082900415553600_bib1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"2025082900415553600_bib2","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2025082900415553600_bib3","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2025082900415553600_bib4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2025082900415553600_bib5","doi-asserted-by":"publisher","first-page":"D2","DOI":"10.1093\/eurheartj\/suv035","article-title":"Why do we need observational studies of everyday patients in the real-life setting?","volume":"17","author":"Cohen","year":"2015","journal-title":"Eur Heart J Suppl"},{"key":"2025082900415553600_bib6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2025082900415553600_bib7","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/ndt\/gfaa150","article-title":"Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study","volume":"36","author":"Kramers","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2025082900415553600_bib8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025082900415553600_bib9","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1681\/ASN.2018090902","article-title":"Automatic measurement of kidney and liver volumes from MR images of patients affected by autosomal dominant polycystic kidney disease","volume":"30","author":"van Gastel","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2025082900415553600_bib10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025082900415553600_bib11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025082900415553600_bib12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025082900415553600_bib13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2025082900415553600_bib14","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ekir.2021.11.034","article-title":"Long-term outcomes of longitudinal efficacy study with tolvaptan in ADPKD","volume":"7","author":"Higashihara","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025082900415553600_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","article-title":"An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International","volume":"37","author":"Muller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2025082900415553600_bib16","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.ekir.2022.02.009","article-title":"Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD","volume":"7","author":"Zhou","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025082900415553600_bib17","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3390\/ijms25042088","article-title":"Long-term effects of tolvaptan in autosomal dominant polycystic kidney disease: predictors of treatment response and safety over 6 years of continuous therapy","volume":"25","author":"Yamazaki","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025082900415553600_bib18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2025082900415553600_bib19","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"key":"2025082900415553600_bib20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/ndt\/gfab278","article-title":"Vaptans or voluntary increased hydration to protect the kidney: how do they compare?","volume":"38","author":"Bankir","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025082900415553600_bib21","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025082900415553600_bib22","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.34067\/KID.0000000000000302","article-title":"Comparing effects of tolvaptan and instruction to increase water consumption in ADPKD: post hoc analysis of TEMPO 3:4","volume":"4","author":"Gobburu","year":"2023","journal-title":"Kidney360"},{"key":"2025082900415553600_bib23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int"},{"key":"2025082900415553600_bib24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/ndt\/gfad218","article-title":"Effects of salt and protein intake on polyuria in V2RA-treated ADPKD patients","volume":"39","author":"Geertsema","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025082900415553600_bib25","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1681\/ASN.2013111184","article-title":"Predictors of autosomal dominant polycystic kidney disease progression","volume":"25","author":"Schrier","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2025082900415553600_bib26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13063-024-07952-x","article-title":"HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial","volume":"25","author":"Bais","year":"2024","journal-title":"Trials"},{"key":"2025082900415553600_bib27","doi-asserted-by":"publisher","first-page":"e0178488","DOI":"10.1371\/journal.pone.0178488","article-title":"Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease","volume":"12","author":"Sharma","year":"2017","journal-title":"PLoS One"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf048\/62310206\/gfaf048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/9\/1764\/62310206\/gfaf048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/9\/1764\/62310206\/gfaf048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:42:03Z","timestamp":1756442523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/9\/1764\/8058887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,3,6]]},"published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf048","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,3,6]]}}}